Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02269176

Enrollment

330

Registered

2014-10-21

Start date

2000-07-31

Completion date

Unknown

Last updated

2014-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Interventions

DRUGLow dose of telmisartan

DRUGHigh dose of telmisartan

DRUGLow dose of losartan

DRUGHigh dose of losartan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and \< 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) \< 180 mmHg

Exclusion criteria

\- Not specified

Design outcomes

Primary

Measure	Time frame	Description
Changes in mean sitting valley value of DBP	8 weeks after start of treatment	The valley value of blood pressure refers to the blood pressure measured prior to the next administration of antihypertensives

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026